I. POLICY

Transcatheter embolization of uterine arteries as a treatment of uterine fibroids or as a treatment for postpartum uterine hemorrhage may be considered medically necessary.

One repeat transcatheter embolization of uterine arteries to treat persistent symptoms of uterine fibroids after an initial uterine artery embolization may be considered medically necessary (See Policy Guidelines).

Transcatheter embolization for the management of cervical ectopic pregnancy is considered investigational, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated when this procedure is repeated.

Policy Guidelines

Patient Selection Criteria

Initial procedure

There are no specific criteria for uterine artery embolization regarding the size, location, or multiplicity of fibroid tumors. The American College of Obstetricians and Gynecologists (ACOG) has suggested the following general criteria for treatment of fibroid tumors:
• Asymptomatic fibroids of such size that they are palpable abdominally and are a concern to the patient; OR
• Excessive uterine bleeding as evidenced by either profuse bleeding lasting more than 8 days, or anemia due to acute or chronic blood loss; OR
• Pelvic discomfort caused by myomata, either acute severe pain, chronic lower abdominal pain, or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection.
Repeat procedure

One repeat uterine artery embolization (UAE) UAE may be performed when there is documentation of continued symptoms such as bleeding or pain. Repeat procedures may be most appropriate when there are persistent symptoms in combination with findings on imaging of an incomplete initial procedure, as evidenced by continued blood flow to the treated regions. Limited data from case series suggest a high rate of success following repeat procedures for this purpose, with the majority of patients reporting relief of symptoms.

Laparoscopic Occlusion of Uterine Arteries

Laparoscopic occlusion of the uterine arteries using bipolar coagulation is considered investigational, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

II. PRODUCT VARIATIONS

[N] = No product variation, policy applies as stated
[Y] = Standard product coverage varies from application of this policy, see below

[N] Capital Cares 4 Kids                    [N] Indemnity
[N] PPO                                    [N] SpecialCare
[N] HMO                                    [N] POS
[N] SeniorBlue HMO                         [Y] FEP PPO*
[N] SeniorBlue PPO

* Refer to FEP Medical Policy Manual MP-4.01.11 Occlusion of Uterine Arteries Using Transcatheter Embolization. The FEP Medical Policy manual can be found at: www.fepblue.org

III. DESCRIPTION/BACKGROUND

Transcatheter uterine artery embolization (UAE) is a minimally invasive technique that involves the injection of small particles into the uterine arteries to block the blood supply to the uterus and uterine fibroids. It potentially serves as an alternative to hysterectomy. UAE has also been used to treat other conditions including postpartum hemorrhage (PPH) and cervical ectopic pregnancy.
Uterine leiomyomata (i.e., fibroids) are extremely common benign tumors that can be located primarily within the uterine cavity (submucosal fibroids) or on the serosal surface of the uterus. Treatment for uterine fibroids is usually sought when they are associated with menorrhagia, pelvic pain, urinary symptoms (i.e., frequency), or are suspected to be the cause of infertility. Treatment options include medical therapy with gonadotropin agonists or gestagen suppression or various types of surgical therapy. Hysterectomy is considered the definitive surgical treatment for those who no longer wish to maintain fertility. Various types of myomectomy, which describes removal of the fibroid with retention of the uterus, have also been described. Hysteroscopic myomectomy involves removal of submucosal fibroids using either a resectoscope or a laser. Subserosal fibroids can be removed via an open abdominal or laparoscopic approach. Laparoscopic laser coagulation of uterine fibroids is a unique approach in that the fibroid is not physically removed, but instead multiple (up to 75) laparoscopic laser punctures of the uterine fibroids are performed in an effort to devascularize the fibroid and induce atrophy. There is interest in techniques to directly devascularize the uterine fibroid by interrupting the uterine arteries. One technique, uterine artery embolization involves selective catheterization of the uterine arteries with injection of embolization material.

UAE has also been used to control bleeding in other situations such as severe postpartum hemorrhage or in the treatment of cervical ectopic pregnancy.

**Regulatory Status**

In April 2000, Embosphere® Microspheres (Biosphere Medical) were cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for hypervascularized tumors and arteriovenous malformations (AVMs). In November 2002, this product was cleared for marketing specifically for use in uterine fibroid embolization. Since that time, several other devices have been cleared for marketing. In 2003, Contour® Emboli PVA (Boston Scientific) was cleared for the embolization of peripheral hypervascular tumors and peripheral AVMs. In March 2004, the Contour SET™ (Boston Scientific) was cleared by the FDA for treatment of uterine fibroids. In December 2008, Cook Incorporated Polyvinyl Alcohol Foam Embolization Particles received FDA marketing clearance for use in uterine fibroid embolization.
IV. RATIONALE

UAE for treatment of uterine fibroids

Initial UAE procedure

A number of randomized controlled trials (RCTs) evaluating UAE for treatment of uterine fibroids have been published. In addition, there have been several systematic reviews of these RCTs. A 2012 Cochrane review included 5 RCTs comparing UAE to surgery in women with symptomatic uterine fibroids. (2) Pooled analyses did not find statistically significant differences in patient satisfaction with UAE or surgery after 2 years (odds ratio [OR]: 0.69, 95% confidence interval [CI]: 0.40 to 1.21, 5 trials) or 5 years (OR: 0.90, 95% CI: 0.45-1.90, 2 trials). UAE was associated with a lower procedure length, shorter hospital stay, shorter time to resumption of routine activities, and lower likelihood of blood transfusion. There were no significant differences between UAE and surgery in terms of major complications, but there was a higher rate of minor complications and reintervention with UAE.

In 2011, van der Kooij and colleagues published a meta-analysis of RCTs comparing UAE and surgery for treating symptomatic uterine fibroids and presented up to 5-year follow-up data. (3) The investigators identified 11 articles reporting on 5 RCTs. The overall intra-procedural and early post-procedural complication rates were similar with the 2 procedures. However, length of hospital stay, need for blood transfusion, and febrile morbidity were significantly lower in the UAE group compared to the surgery group. At 12 months, a pooled analysis of 2 studies found a significantly higher reintervention rate in the UAE group compared to the surgery group (odds ratio [OR]: 5.78, 95% confidence interval [CI]: 2.14 to 15.58). Pooled analyses of quality-of-life variables at 12 months did not find significant differences between groups. Results were similar after 5 years. The reintervention rate was significantly higher at 5 years, according to a pooled analysis of 2 trials (OR: 5.41, 95% CI: 2.48 to 11.81).

A 2013 systematic review by Martin and colleagues focused on complication and reintervention rates following UAE for symptomatic uterine fibroids. (4) Eight RCTs comparing UAE to another intervention were included. Among the 350 UAE cases in the RCTs, the most common complications were discharge and fever (4%), post-embolization syndrome (2.9%), pain (2.9%) and groin complications (2.9%). Six trials also provided data on 346 cases of surgery for uterine fibroids. The most common complications following surgery were urinary stress incontinence (3.8%), pressure symptoms (2.9%) and menorrhagia (2.6%). Three trials presented reintervention data and, in a meta-analysis of these studies, there was a significantly higher risk of reintervention after UAE compared to surgery, but a
Representative trials are described below:

The Randomized Trial of Embolization versus Surgical Treatment for Fibroids (REST) multicenter trial assigned patients in a 2:1 ratio to undergo UAE (n=106) or surgery (43 hysterectomies and 8 myomectomies). (5) The embolization group had lower postoperative pain (3.0 vs. 4.6, respectively) and faster recovery (e.g., 1- vs. 5-day median hospitalization, respectively). Of 7 identified pregnancies in the UAE group, 2 resulted in successful live births. Five-year follow-up data from the REST trial were published in 2011. (6) A total of 144 of 157 (92%) randomized patients were included in the 5-year analysis. Quality-of-life and symptom scores were similar in the 2 groups at 5 years. For example, the mean symptom score was 4.5 in the UAE group and 4.8 in the surgery group (scores ranged from 15, markedly worse to 5, markedly better). By the 5-year follow-up, 27 of 106 (25%) in the UAE group and 2 of 51 (4%) in the surgery group had received an additional intervention for continued or recurrent symptoms. The total rate of further intervention for symptoms or adverse events over the 5-year period was 32% in the UAE group and 4% after surgery. In the UAE group, there were 3 technical failures of the procedure, 8 repeat UAEs, and 18 hysterectomies. Note that one woman had both a repeat UAE and a hysterectomy, and 2 women were not embolized after randomization and subsequently underwent surgery.

The Embolization versus hysterectomy (EMMY) trial from the Netherlands included 177 women with uterine fibroids and heavy menstrual bleeding who were scheduled to undergo hysterectomy. They were randomized to receive UAE (n=88) or hysterectomy (n=89). (7, 8) By the 2-year follow-up, 19 of the 81 (23%) women who actually received UAE had undergone a hysterectomy. An analysis of health-related quality of life (HRQOL) outcomes at 2 years found similar improvement in both groups overall. The defecation distress inventory (DDI) score improved significantly in only the UAE group starting at 6 months. A report of 5-year outcome data from the EMMY trial was published in 2010. (9) A total of 70 of the 89 (79%) patients originally randomized to the hysterectomy group and 75 of 88 (85%) in the UAE group completed questionnaires at 60 months. In an intention-to-treat (ITT) analysis, 23 of 81 (28.4%) women who had received UAE underwent hysterectomy during the 5 years. Including the hysterectomies, 58 of 81 (71.6%) women in the UAE group no longer had menorrhagia. There were no significant differences between groups in health-related quality of life at 5 years, as assessed by mental and physical components of the Short Form-36 (SF-36). For example, the mean difference in change scores at 60 months on the physical component summary of the SF-36 was 1.26 (95% CI: 2.16 to 4.70). Within the hysterectomy group, there was a statistically significantly worse physical health score at 5 years (mean of 6.87) compared to 2 years (mean of 7.26), p=0.01. The UAE group did not
have a significant change in the mean physical health score, which was 6.87 at 5 years and 5.80 at 2 years, p=0.34. There was also not a statistically significant difference in the rate of reported urinary incontinence. Similar to the 2-year finding, the DDI significantly improved over time in the UAE group but not in the group assigned to initial hysterectomy. There was not, however, a statistically significant difference between groups in defecation function at 5 years. The authors did not discuss their level of statistical power to detect between-group differences.

In 2012, findings of the Fibroids of the Uterus: Myomectomy versus Embolization (FUME) trial from the U.K. were published. (10) The investigators randomized women with symptomatic fibroids to UAE (n=82) or myomectomy (n=81). Mean hospital stay was significantly shorter after UAE than surgery (2 vs. 4 days, respectively; p<0.0001). There were no significant differences in minor or major complications. A total of 120 of 163 (74%) were available for the analysis of quality of life, the primary outcome measure. There were no significant differences between groups in change in quality-of-life scores from baseline to 1 year. Nine patients (11%) in the UAE group required additional intervention, and 3 patients (4%) in the myomectomy group later underwent hysterectomy.

An RCT by Hald and colleagues in Norway evaluated clinical outcomes in 66 premenopausal women (mean age: 43 years) with symptomatic uterine fibroids who were randomized to treatment with either laparoscopic occlusion of uterine arteries or UAE. (11) Women who wanted to bear children in the future, had a large uterus, had undergone multiple previous open abdominal surgeries, and who had bleeding disorders were excluded. The primary outcome was reduction in blood loss at 6 months’ post-intervention, as measured by a pictorial blood loss assessment chart. Fifty-eight women underwent treatment, 29 with UAE and 29 with laparoscopic occlusion. The proportion of women who had a reduction in blood loss after 6 months did not differ between the treatment groups (52% after UAE and 53% after laparoscopy, respectively; p=0.96). An additional publication reported on follow-up data at a median of 48 months after treatment (range: 8-73 months). (12) The cumulative clinical failure and recurrence rate was significantly lower for patients in the UAE group (17%, n=5) compared to the laparoscopy group (48%, n=17), p=0.02. Moreover, fewer patients in the UAE group (7%, n=2) had a hysterectomy than in the laparoscopy group (28%, n=8), p=0.41. The authors concluded that UAE is superior to laparoscopic UAO for treatment of uterine fibroids.

Section summary: There is evidence from RCTs that the net health outcome after UAE for uterine fibroids is reasonable compared to surgery. Meta-analyses of RCTs have found similar levels of quality of life after 5 years among women receiving UAE or surgery, although there were more reinterventions in the UAE group.
 Repeat UAE to treat recurrent or persistent symptoms

No RCTs focusing on repeat UAE were identified; there are published case series. In 2009, McLucks and colleagues published a study in which the charts of 1,058 women who had undergone initial bilateral UAE at several U.S. centers were reviewed. (13) Forty-two (4%) patients had documentation of persistent symptoms, and they were offered a second bilateral UAE. Thirty-nine patients had repeat procedures, and 34 of these (87%) completed a follow-up questionnaire at least 6 months postembolization. Before the second UAE procedure, 27 of the 34 (79%) women reported severe bleeding, and only 2 (6%) women reported severe bleeding after the procedure. Similarly, the number of women with severe pain decreased from 20 (59%) to 2 (6%), and with severe pressure decreased from 18 (53%) to 2 (6%). A total of 4 individuals experienced severe levels of one or more symptoms after the second UAE. Prospective comparative studies are needed to confirm the findings.

In 2006, Yousefi and colleagues reported on 24 patients who underwent repeat embolization for recurrent or persistent symptoms 6-66 months after the initial procedure. (14) The most common symptoms were pressure and/or bulk symptoms (n=15), recurrent heavy bleeding (n=12), and pelvic pain or cramping (n=7). Follow-up data were available on 21 of 24 (87.5%) after the second UAE; 19 (90%) reported symptom control.

Section summary: There is a lack of RCTs on repeat UAE for treatment of symptoms associated with uterine fibroids. However, there are data from case series showing a high rate of success after a second UAE for recurrent or persistent symptoms.

UAE for treatment of postpartum uterine hemorrhage (PPH)

No RCTs or other comparative studies evaluating UAE for treating PPH were identified. In 2012, Rath and colleagues published a systematic review of literature on second-line treatment of PPH. (15) The authors stated that there is a lack of RCTs on arterial embolization for UAE and the emergent and multi-factorial nature of this condition, as well as potential ethical issues, makes it difficult to conduct a randomized trial. The review summarized the success rate of arterial embolization for PPH reported in case series as ranging from 70-100%, and from 60-83% in placenta accreta. The authors noted that UAE should not be performed in patients with excessive bleeding or when the patient is hemodynamically unstable.

Representative larger case series are described below:

In 2011, Ganguli and colleagues published data on 66 women who underwent UAE for the treatment of postpartum hemorrhage. (16) The clinical success rate, defined as obviation of
hysterectomy, was 95%. Three of 66 (5%) women had a subsequent hysterectomy. In addition to the 3 clinical failures, there were 3 (5%) major complications after UAE: one case of lower-extremity deep vein thrombosis, one case of postprocedural pancreatitis, and one admission for intravenous antibiotic treatment for presumed endometritis. Nine pregnancies after UAE were identified; there were 2 spontaneous abortions and 7 viable gestations.

In 2009, Kirby and colleagues published a retrospective analysis of data from 43 women who underwent UAE for primary PPH. (17) In this study, clinical success was defined as cessation of bleeding without need for repeat embolization, laparotomy or hysterectomy and without mortality. Eight of 43 (19%) of women had a hysterectomy prior to UAE. Of the remaining 35 women, clinical success was achieved in 29 women (83%). Considering the sample as a whole, the clinical success rate was 29 of 43 (67%). Complications among women who had a UAE without a previous hysterectomy included one case of a groin hematoma, one inadvertent perforation of the left obturator artery during UAE, one bleeding necrotic fibroid tumor, and one case of symptoms consistent with endometritis.

Section summary: There is a lack of RCTs on repeat UAE for treatment of postpartum hemorrhage. Conducting RCTs may be particularly difficult in this emergent and clinically complex situation. Data from case series have shown a high rate of success after UAE for postpartum hemorrhage.

UAE for treatment of cervical ectopic pregnancy

No RCTs or other comparative studies evaluating UAE for treating cervical ectopic pregnancy were identified. The published literature consisted of case series with small numbers of patients. Sample sizes ranged from 2 to 20 patients, and most studies had fewer than 10 patients. The largest prospective series was conducted in China by Xiaolin and colleagues. (18) Patients underwent UAE and in conjunction with methotrexate injections before, during, and after the UAE procedure. Median follow-up was 12 months (range 1 to 50 months). Two of 20 patients (10%) had recurrent vaginal bleeding; the other 18 had no significant bleeding after UAE. Five patients (25%) had an additional curettage procedure due to bleeding and/or high levels of beta (b)-hCG. The uterus was preserved in all patients, and normal menses resumed after 2 to 4 months. Eight of 16 (50%) women who attempted another pregnancy achieved a normal pregnancy within 1 year. There were 2 miscarriages and 6 live births at term.

Section summary: There is a lack of RCTs in UAE for treating cervical ectopic pregnancy and only a few small case series were available.
Impact of UAE treatment on fertility and pregnancy outcomes

A 2013 systematic review by Mohan and colleagues identified 21 studies reporting pregnancy outcomes and/or pregnancy complications after UAE for treatment of uterine fibroids or postpartum hemorrhage. (19) The authors reported that the cumulative pregnancy and miscarriage rates among women trying to conceive following UAE for uterine fibroids was 59% and 28%, respectively and the cumulative live birth rate was 65%. The term delivery rate was 61%. In the studies on UAE for PPH, the cumulative pregnancy rate, based on a small number of pregnancies, was 87.2%. Rates of miscarriage and live births were not reported following UAE for PPH. Most of the studies included in the systematic review were observational and had no or inadequate controls. There was only one RCT. This study, by Mara and colleagues in Czech Republic, randomized 121 women with uterine fibroids who desired future pregnancies to UAE or myomectomy. (20) Participants were followed-up for a mean of 25 months; they were advised to wait for at least 6 months after the procedure before they attempted pregnancy. At final follow-up, 13 of 26 women (50%) in the UAE group who tried to conceive became pregnant compared to 31 of 40 (76%) in the myomectomy group; the difference between groups was not statistically significant. Among women in the UAE group who became pregnant, the abortion rate was 64% and the delivery rate was 19%. In the myomectomy group, the abortion rate was 23%, and the delivery rate was 48%.

Previously, a 2010 systematic review was published that identified a total of 227 pregnancies after UAE for uterine fibroids from 8 published reports. (21) Miscarriage rates were compared to a control group of 1,121 pregnancies in women with intramural fibroids from 14 studies. The overall pooled miscarriage rate was 80 of 227 (35.2%) in the UAE group compared to 185 of 1,121 (16.5%) in the fibroid group, p<0.001. In addition, the review compared obstetric outcomes in women with UAE to a control group of 4,454 women from 10 studies on pregnancies complicated by fibroids. The rate of Cesarean section was significantly higher in the UAE group (66%) than in the fibroid group (48.6%), p<0.001. There was also a significantly higher rate of postpartum hemorrhage in the UAE group compared to the fibroid group, 14% versus 2.5%, p<0.001. Rates of preterm delivery, malpresentation, and intra-uterine growth retardation (IUGR) did not differ significantly between groups.

Section summary: Reviews of fertility and pregnancy outcomes after UAE suggest that successful pregnancy is possible after UAE for treatment of uterine fibroids or PPH. One review found higher rates of miscarriage and postpartum hemorrhage after UAE for treatment of uterine fibroids compared to treatment of fibroids with myomectomy. There are limited data on pregnancy outcomes in women who became pregnant following UAE for treatment of PPH.
Ongoing Clinical Trials

The FIRSST: Comparing MRgFUS (MR guided Focused Ultrasound) versus UAE (Uterine Artery Embolization) (NCT00995878) (22): This is an RCT comparing MRgFUS to UAE in premenopausal women at least 25 years of age who have symptomatic uterine fibroids. The primary outcome is reduction in symptoms, including pain, as assessed by validated instruments. The expected enrollment is 180 participants and the expected date of study completion is December 2015.

Uterine Artery Embolization (UAE) Versus High-Intensity-Focused-Ultrasound (HIFU) for Treatment of Uterine Fibroids (NCT01834703) (23): This RCT is testing the safety and efficacy of HIFU compared to UAE in women aged 30 to 47 with uterine fibroids. The primary outcome is the treatment success rate after 6 months. The investigators plan to enroll 200 women and the estimated study completion date is May 2014.

Clinical Input Received through Specialty Medical Societies and Academic Medical Centers

In response to requests, input was received through 3 Physician Specialty Societies and 2 Academic Medical Centers while this policy was under review in 2012. While the various Physician Specialty Societies and Academic Medical Centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the Physician Specialty Societies or Academic Medical Centers, unless otherwise noted. There was consensus among reviewers that UAE is medically necessary for treating uterine fibroids and near-consensus agreement that UAE is medically necessary for treating postpartum hemorrhage, particularly for the indications stated in the ACOG practice bulletin No. 76 (described in more detail below). (25) Clinical input was mixed on repeat UAE and UAE for managing cervical ectopic pregnancy. One reviewer who disagreed that repeat UAE is investigational provided detailed input on clinical situations in which a repeat procedure might be appropriate.

Summary

Uterine artery embolization (UAE) involves selective catheterization of the uterine arteries with injection of embolization material. The available evidence suggests that the net health outcome after UAE for uterine fibroids is reasonable compared to surgery. Although there are a lack of controlled studies on repeat UAE, case series have found a high rate of success after a second UAE for recurrent or persistent symptoms. Thus, UAE for initial treatment of uterine fibroids and one repeat UAE to treat persistent symptoms may be considered medically necessary.
There are no controlled studies evaluating UAE for postpartum hemorrhage or cervical ectopic pregnancy. However, due to available evidence from case series and strong support from clinical reviewers, UAE for postpartum hemorrhage may be considered medically necessary. In the absence of either controlled studies or strong clinical support, UAE for management of cervical ectopic pregnancy is considered investigational.

Practice Guidelines and Position Statements

In 2004, the American College of Obstetricians and Gynecologists (ACOG) issued a committee opinion on UAE. (24) The statement offered the following conclusions: “…. There is insufficient evidence in the current literature to ensure safety in women desiring to retain their fertility. Furthermore, pregnancy-related outcomes remain understudied. Therefore, the procedure should be considered investigational or relatively contraindicated in women wishing to retain fertility. The use of uterine artery embolization in postmenopausal women is rarely, if ever, indicated.” In August 2008, ACOG issued a Practice Bulletin titled “Alternatives to Hysterectomy in the Management of Leiomyomas.” (25) This Bulletin contained the following statement regarding UAE: “Based on long- and short-term outcomes, uterine artery embolization is a safe and effective option for appropriately selected women who wish to retain their uterii.”

2010 Quality Improvement Guidelines from the Society of interventional Radiology stated that uterine artery embolization is indicated in women with uterine leiomyomas that are causing significant symptoms. (26) Absolute contraindications to UAE are viable pregnancy, active infection, and suspected uterine, cervical, or adnexal malignancy (unless the procedure is being performed for palliation or in conjunction with surgery). A desire to maintain fertility is a relative contraindication.

In 2008 ACOG reaffirmed a practice bulletin (No. 76) on management of postpartum hemorrhage. (25) The bulletin states that UAE may be indicated under the following circumstances:

“A patient with stable vital signs and persistent bleeding, especially if the rate of loss is not excessive, may be a candidate for arterial embolization. Radiographic identification of bleeding vessels allows embolization with Gelfoam, coils, or glue. Balloon occlusion is also a technique used in such circumstances. Embolization can be used for bleeding that continues after hysterectomy or can be used as an alternative to hysterectomy to preserve fertility.”
V. DEFINITIONS

**Embolization** refers to the obstruction of a blood vessel by intentionally injected material, or by physiologic migration of loosened intravascular plaque or thrombi.

**Gestagen Suppression** is the use of natural or synthetic hormones to alter reproductive physiology.

**Gonadotropin Releasing Hormone Agonists** are drugs that block the release of the reproductive hormones LH (luteinizing hormone) and FSH (follicle stimulating hormone). As a result, ovarian estrogen production is reduced. Agonists include leuprolide and a nasal spray, Nafarelin.

**Hysterectomy** is the surgical removal of the uterus.

**Laparoscopy** is an abdominal or pelvic exploration using a telescope-like instrument called a laparoscope.

**Menorrhagia** is menstrual bleeding that is excessive in the number of days or amount of blood, or both.

VI. BENEFIT VARIATIONS

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member’s individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member’s benefit information or contact Capital for benefit information.

VII. DISCLAIMER

Capital’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.
VIII. REFERENCES


IX. CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

[Note: Final page is signature page and is kept on file, but not issued with Policy.]
**MEDICAL POLICY**

**POLICY TITLE**
OCCLUSION OF UTERINE ARTERIES USING TRANSCATHETER EMBOLIZATION OR LAPAROSCOPIC OCCLUSION TO TREAT UTERINE FIBROIDS

**POLICY NUMBER**
MP-7.007

Covered when medically necessary:

<table>
<thead>
<tr>
<th>CPT Codes®</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>36245</td>
<td>36246</td>
</tr>
<tr>
<td>36247</td>
<td>36248</td>
</tr>
<tr>
<td>37241</td>
<td>37242</td>
</tr>
<tr>
<td>37243</td>
<td>37244</td>
</tr>
<tr>
<td>75736</td>
<td></td>
</tr>
<tr>
<td>75894</td>
<td>75898</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>ICD-9-CM Diagnosis Code*</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>218.0</td>
<td>SUBMUCOUS LEIOMYOMA OF UTERUS</td>
</tr>
<tr>
<td>218.1</td>
<td>INTRAMURAL LEIOMYOMA OF UTERUS</td>
</tr>
<tr>
<td>218.2</td>
<td>SUBSEROUS LEIOMYOMA OF UTERUS</td>
</tr>
<tr>
<td>218.9</td>
<td>LEIOMYOMA OF UTERUS, UNSPECIFIED</td>
</tr>
<tr>
<td>219.0 – 219.9</td>
<td>OTHER BENIGN NEOPLASM OF UTERUS</td>
</tr>
<tr>
<td>280.0</td>
<td>IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC)</td>
</tr>
<tr>
<td>285.1</td>
<td>ACUTE POSTHEMORRHAGIC ANEMIA</td>
</tr>
<tr>
<td>666.00-666.24</td>
<td>POSTPARTUM HEMORRHAGE (code range)</td>
</tr>
</tbody>
</table>

*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.

The following ICD-10 diagnosis codes will be effective October 1, 2014

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code*</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D25.0</td>
<td>Submucous leiomyoma of uterus</td>
</tr>
<tr>
<td>D25.1</td>
<td>Intramural leiomyoma of uterus</td>
</tr>
<tr>
<td>D25.2</td>
<td>Subserosal leiomyoma of uterus</td>
</tr>
<tr>
<td>D25.9</td>
<td>Leiomyoma of uterus, unspecified</td>
</tr>
</tbody>
</table>

*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.

[Note: Final page is signature page and is kept on file, but not issued with Policy.]
MEDICAL POLICY

<table>
<thead>
<tr>
<th>POLICY TITLE</th>
<th>OCCLUSION OF UTERINE ARTERIES USING TRANSCATHETER EMBOLIZATION OR LAPAROSCOPIC OCCLUSION TO TREAT UTERINE FIBROIDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>POLICY NUMBER</td>
<td>MP-7.007</td>
</tr>
</tbody>
</table>

X. POLICY HISTORY

<table>
<thead>
<tr>
<th>POLICY NUMBER</th>
<th>DATE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP 7.007</td>
<td>CAC 8/30/05</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAC 6/27/06</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAC 6/26/07</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAC 7/31/07</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAC 7/29/08</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAC 7/28/09</td>
<td>Consensus Review</td>
</tr>
<tr>
<td></td>
<td>10/26/10</td>
<td>Adopt BCBSA</td>
</tr>
<tr>
<td></td>
<td>CAC 7/26/11</td>
<td>Minor revision. Removed “symptomatic” from medical necessity statement.</td>
</tr>
</tbody>
</table>

**CAC 10/30/12 Minor revision.** Postpartum uterine hemorrhage added to medically necessary statement. Investigational statement added on UAE for management cervical ectopic pregnancy. Statement on repeat UAE changed to state that one repeat procedure may be considered medically necessary. Information on patient selection added to Policy Guidelines. Added FEP variation referencing FEP policy manual. Codes reviewed 9/24/12 klr

<table>
<thead>
<tr>
<th>POLICY NUMBER</th>
<th>DATE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CAC 11/26/13</td>
<td>Consensus review. References updated, but no changes to the policy statements. Rationale added.2014 New codes added to policy.</td>
</tr>
</tbody>
</table>

*Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.*

[Note: Final page is signature page and is kept on file, but not issued with Policy.]